Stride gets US FDA nod for Keterolac Tromethamine

New Delhi, July 18: Pharma company Strides Arcolab Ltd today said it has received US Food and Drug Administration (FDA) approval for Keterolac Tromethamine injection.

The product will be available in the strenghs of 15 and 30 mg/mL, a press release said.

Ketrolac is the first approval amongst 22 sterile submissions the company has submitted with US FDA and follows a successful FDA approval of its sterile manufacturing facility in India.

Vice Chairman and Managing Director of the company Arun Kumar said in the release, ''We are excited with our first sterile injectable approval and are delighted having achieved a key milestone in creating a global sterile injectable business.''

UNI